Results

1–10 of 39 results for anti-VEGF therapy

Reduced Rates of Diabetic Retinopathy Complications With Use of Continuous Glucose Monitoring: A Multicenter Population-Based Study
Amer F Alsoudi, MD
Annual Meeting Talks
2025
Lower Socioeconomic Status Is Associated With Increased Bevacizumab Use Among Patients Initiating Anti-VEGF Therapy for Diabetic Macular Edema
Judy E. Kim, MD, FASRS
Annual Meeting Talks
2025
Outcomes of Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States Who Were Lost to Follow-up
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2025
Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections
Sean David Adrean, MD, FAAO, FASRS
Annual Meeting Talks
2025
Safety of Continuing Anti-VEGF Therapy Around the Time of Nonophthalmic Incisional Surgery: A Multisite Matched Cohort Study
Odette M. Houghton, MD
Updates from the Field
2026
Daily Imaging With Home Optical Coherence Tomography Among Treatment-Naive Neovascular Age-Related Macular Degeneration Participants
Kevin J. Blinder, MD, FASRS
Annual Meeting Talks
2023
Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2023
Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Annual Meeting Talks
2024
Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024
Subretinal Delivery of Investigational ABBV-RGX-314 for Neovascular Age-Related Macular Degeneration: A Phase II Pharmacodynamic Study
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2024